Dysnatremia, its correction, and mortality in patients undergoing continuous renal replacement therapy: a prospective observational study

Seung Seok Han1, Eunjin Bae1, Dong Ki Kim1,2, Yon Su Kim1,2, Jin Suk Han1,2 and Kwon Wook Joo1,2*

Abstract

Background: Although dysnatremia has been reported to be correlated with mortality risk, this issue remains unresolved in patients undergoing continuous renal replacement therapy (CRRT). Furthermore, it has not been determined whether change in or correction of sodium is related to mortality risk in this subset.

Methods: A total of 569 patients were prospectively enrolled at the start of CRRT between May 2010 and September 2013. The patients were divided into 5 groups: normonatremia (135–145 mmol/L), mild hyponatremia (131.1–134.9 mmol/L), moderate to severe hyponatremia (115.4–131.0 mmol/L), mild hypernatremia (145.1–148.4 mmol/L), and moderate to severe hypernatremia (148.5–166.0 mmol/L). The non-linear relationship between sodium and mortality was initially explored. Subsequently, the odds ratios (ORs) for 30-day mortality were calculated after adjustment of multiple covariates.

Results: The relationship between baseline sodium and mortality was U-shaped. The mild hyponatremia, moderate to severe hyponatremia, and moderate to severe hypernatremia groups had greater ORs for mortality (1.65, 1.91, and 2.32, respectively) than the normonatremia group (all P values < 0.05). However, later sodium levels (24 and 72 h after CRRT) did not predict 30-day mortality. Furthermore, the changes in sodium over 24 or 72 h, including the appropriate correction of dysnatremia, did not show any relationships with mortality, irrespective of baseline sodium level.

Conclusions: Sodium level at the start of CRRT was a strong predictor of mortality. However, changes in sodium level and the degree of sodium correction were not associated with the mortality risk in the patients with CRRT.

Keywords: Continuous renal replacement therapy, Dysnatremia, Hypernatremia, Hyponatremia, Mortality

Background

Both hyponatremia and hypernatremia are important risk factors for high morbidity and mortality in several clinical settings [1, 2]. However, reports have conflicted about the dependent and independent relationships of sodium with mortality. A relationship is plausible because both hyponatremia and hypernatremia have adverse consequences via their effects on the brain, heart, and other organs [3, 4]. However, dysnatremia might be only a marker of comorbidities, with deaths attributable mainly to the severity of the diseases and not to dysnatremia itself [5]. A recent review of hyponatremia cases concluded that deaths were associated with the underlying illness, rather than with the severity of hyponatremia [6]. Given the nature of this issue, it is unclear whether the correction of sodium can reduce the mortality risk. Most randomized controlled trials of drugs for sodium correction have not demonstrated a survival advantage [7]. Although these results have not excluded the need for sodium correction, it is necessary to address whether sodium correction alone can reduce mortality. A well-designed observational study could be helpful because randomized controlled trials for this issue are not feasible.
Continuous renal replacement therapy (CRRT) is increasingly used in severe acute kidney injury (AKI), because it can easily control biochemical imbalances due to AKI [8]. The presence of AKI or comorbidities hinders the effectiveness of conventional fluid or drug management, but CRRT can overcome these difficulties and achieve normonatremia. Here, we first addressed how sodium levels predict mortality in a prospective cohort of patients receiving CRRT, in whom the control of dysnatremia was extremely difficult with conventional treatment alone. Whether sodium correction is independently associated with reduced mortality in comorbid conditions was also addressed.

Methods
Participants and data collection
Data on patients undergoing CRRT were obtained prospectively from a cohort from the tertiary referral center (Seoul National University Hospital). The inclusion criteria were as follows: CRRT was needed due to severe AKI; and the patient’s age was 18 years old or older. Accordingly, a total of 669 patients were enrolled at the start of CRRT from May 2010 to September 2013. All of the patients who participated in the present study provided informed consent and agreed with serial examination of serum sodium in adherence to the study protocol. We excluded patients who were previously diagnosed with end-stage renal disease or who received dialysis before enrollment (n = 97). If the patients underwent CRRT more than once (n = 3), only the first experience was counted as a single case. Consequently, 569 patients were analyzed for the present study. Flow diagram for this process is shown in Additional file 1.

Clinical parameters, such as age, sex, weight, cause of AKI, dialysis dose, the need for mechanical ventilation, the use of vasoactive drugs, and underlying chronic kidney disease, were recorded at the start of CRRT. The causes of AKI were divided into sepsis, surgery, nephrotoxin, and others. Information on comorbidities was collected and was presented as Charlson Comorbidity Index [9]. The Acute Physiology and Chronic Health Evaluation (APACHE) II score was calculated to quantitatively assess each patient’s status [10]. Serum sodium, creatinine, and albumin were measured (Toshiba-200FR, Toshiba, Tokyo, Japan), and the urine output data during the first 2 h of CRRT were recorded. Serum sodium was additionally measured at 24 and 72 h after CRRT. Fluid balance before evaluation of later sodium levels (24 and 72 h) was monitored and expressed as follows: fluid balance = total input − total output. There were no missing data for any of the variables. Corrected sodium values for serum glucose were used in the study analyses, based on the following formula: corrected sodium = measured sodium + 0.016 × (serum glucose − 100) [11]. The onsets of dysnatremia were presented as acute (duration < 48 h), chronic (≥ 48 h), or unknown duration. If dysnatremia was identified, it was treated using CRRT with diluted or concentrated substitution fluid to control the speed of correction [12, 13].

The primary outcome was 30-day all-cause mortality after starting CRRT. The mortality data were obtained from the national database of Statistics Korea; all Koreans have a resident registration number and death events are recorded and stored at a national level.

The study protocol complies with the Declaration of Helsinki and received full approval from the institutional review board at the Seoul National University Hospital (no. 1309-018-518). No extramural funding was used to support this work. The authors are solely responsible for the design and conduct of this study, all study analyses and drafting and editing of the paper.

Statistical analysis
All of the analyses and calculations were performed using STATA software (version 12.0, StataCorp LP, College Station, Texas, USA). The data are presented as the mean ± standard deviations for continuous variables and as proportions for categorical variables. Based on variable distributions using histograms, the variables with non-normal distributions are expressed as the median (interquartile ranges). The chi-squared test was used to compare the categorical variables. Comparisons between normally distributed continuous variables were performed using an analysis of variance or a post-hoc analysis of least significant difference, according to the number of comparison groups. Comparisons between non-normally distributed continuous variables were performed by either the Kruskal-Wallis test or the Mann–Whitney U test, depending on the number of comparison groups. The dose–response relationship (in particular, the non-linear relationship) between sodium and mortality was initially explored by a restricted cubic spline analysis. Due to the U-shaped relationship, we divided the patients into five groups as follows: normonatremia (135–145 mmol/L), mild hyponatremia, moderate to severe hyponatremia, mild hypernatremia, and moderate to severe hypernatremia. The mild and moderate to severe dysnatremia groups were determined based on the median sodium value within each hypo- and hypernatremia group. Survival curves were drawn using the Kaplan–Meier method. To compare survival curves between groups, the log-rank test was initially applied. The odds ratios (ORs) and 95% confidence intervals (CIs) for 30-day mortality were calculated using the logistic regression model after adjustment of all covariates (as provided in Table 1). A P value less than 0.05 was considered significant.

Results
Baseline characteristics
The baseline characteristics of the patients are shown and compared between groups with respect to serum
sodium level in Table 1. For the 569 subjects, the mean age was 63 years. Except for one Caucasian subject, all other patients were Asian. Approximately half received CRRT because of sepsis. The ranges of sodium levels in dysnatremia groups were as follows: mild hyponatremia, 131.1–134.9 mmol/L; moderate to severe hyponatremia, 115.4–131.0 mmol/L; mild hypernatremia, 145.1–148.4 mmol/L; and moderate to severe hypernatremia, 148.5–166.0 mmol/L. The subjects were followed for a median of 19 days (4 to 193 days).

Table 1 Baseline characteristics and laboratory findings of the patients at the time of admission to the intensive care unit

| Sodium group | Moderate to severe hyponatremia (n = 111) | Mild hyponatremia (n = 112) | Normonatremia (n = 247) | Mild hypernatremia (n = 49) | Moderate to severe hypernatremia (n = 50) | Total (n = 569) |
|--------------|------------------------------------------|-----------------------------|-------------------------|----------------------------|------------------------------------------|----------------|
| Age (years)  | 63.2 ± 14.94                             | 64.3 ± 15.37                | 63.9 ± 14.38            | 60.9 ± 16.15               | 59.7 ± 17.46                           | 63.2 ± 15.14 |
| Male sex (%) | 56.8                                     | 61.6                        | 62.3                    | 61.2                       | 56.0                                    | 60.5           |
| Enrollment year (%) |                                           |                             |                         |                            |                                          |                |
| 2010         | 15.3                                     | 13.4                        | 14.6                    | 14.3                       | 10.0                                    | 14.1           |
| 2011         | 29.7                                     | 33.0                        | 32.4                    | 16.3                       | 32.0                                    | 30.6           |
| 2012         | 33.3                                     | 34.8                        | 35.6                    | 46.9                       | 40.0                                    | 36.4           |
| 2013         | 21.6                                     | 18.8                        | 17.4                    | 22.4                       | 18.0                                    | 19.0           |
| Body weight (kg) |                                             |                             |                         |                            |                                          |                |
| 62.2 ± 11.56 | 64.3 ± 13.19                             | 63.6 ± 14.02                | 65.5 ± 12.48            | 62.3 ± 10.62               | 63.5 ± 13.00                           |                |
| Cause of acute kidney injury (%)*   |                                           |                             |                         |                            |                                          |                |
| Sepsis       | 44.1 †                                   | 55.4                        | 49.4                    | 55.1                       | 36.0*                                   | 48.9           |
| Surgery      | 3.6                                      | 6.2                         | 11.7                    | 8.2                        | 8.0                                     | 8.4            |
| Nephrotoxin  | 5.4                                      | 4.5                         | 8.1                     | 6.1                        | 4.0                                     | 6.3            |
| Other        | 46.8                                     | 33.9                        | 30.8                    | 30.6                       | 52.0                                    | 36.4           |
| Dialysis dose (mL/kg/hour) | 41.9 ± 15.43                             | 47.7 ± 18.61                | 45.0 ± 16.99            | 46.2 ± 19.19               | 41.7 ± 15.90                           | 44.8 ± 17.21  |
| Need for MV (%) |                                           |                             |                         |                            |                                          |                |
| 76.6         | 83.9                                     | 85.0                        | 93.9                    | 80.0                       | 83.5                                    |                |
| Use of vasoactive drugs (%) | 73.0                                     | 68.8                        | 72.1                    | 67.3                       | 74.0                                    | 71.4           |
| Chronic kidney disease (%) | 48.6                                     | 46.4                        | 42.5                    | 26.5*                      | 34.0                                    | 42.4           |
| Charlson Comorbidity Index †       | 3.5 ± 2.18 †                             | 3.3 ± 2.25*                 | 2.7 ± 2.13              | 2.5 ± 2.05                 | 2.5 ± 1.98                             | 2.9 ± 2.17    |
| APACHE II score*            | 29.6 ± 9.56                              | 28.3 ± 7.91                 | 28.7 ± 8.00             | 30.6 ± 8.05                | 32.5 ± 8.15 †                          | 29.3 ± 8.38   |
| Blood findings                                           |                                           |                             |                         |                            |                                          |                |
| Sodium (mmol/L) ‡      | 126.6 ± 3.99 ‡                           | 133.2 ± 1.09 ‡              | 139.5 ± 2.74            | 146.8 ± 0.92 ‡             | 154.0 ± 4.81 ‡                          | 137.6 ± 8.27  |
| Creatinine (mg/dL)*    | 3.3 ± 2.01                               | 3.7 ± 2.67 †                | 3.1 ± 1.61              | 2.8 ± 1.27                 | 2.9 ± 1.69                             | 3.2 ± 1.94    |
| Albumin (g/dL)         | 2.7 ± 0.57                               | 2.6 ± 0.52 †                | 2.7 ± 0.52              | 2.6 ± 0.51                 | 2.7 ± 0.50                             | 2.7 ± 0.53    |
| Glucose (mg/dL) †      | 139 (108–190)                            | 147 (116–196)               | 153 (113–229)           | 164 (119–222)              | 191 (134–311) †                        | 152 (115–218) |
| Urine output (mL/2 hours)| 15 (0–70)                                | 20 (0–55)                   | 20 (0–90)               | 30 (0–118)                 | 28 (4–64)                              | 20 (0–78)     |
| Fluid balance                                          |                                           |                             |                         |                            |                                          |                |
| During 24 h (mL) †     | 808.3 ± 1527.1861                        | 1069.0 ± 2242.01            | 1250.7 ± 1971.14        | 1736.9 ± 2378.86           | 2772.3 ± 2555.26 †                     | 1304.2 ± 2103.42 |
| During 72 h (mL) †     | 816.1 ± 2066.11                          | 1036.9 ± 3773.28           | 999.2 ± 2854.91         | 1957.4 ± 3839.81           | 2611.9 ± 2918.75 †                     | 1185.9 ± 3197.57 |
| Onset of dysnatremia (%) |                                           |                             |                         |                            |                                          |                |
| Acute         | 198                                      | 34.8                        | –                       | 77.6                       | 48.0                                    | 38.2 §         |
| Chronic       | 61.3                                     | 46.4                        | –                       | 10.2                       | 30.0                                    | 43.5           |
| Unknown       | 18.9                                     | 18.8                        | –                       | 12.2                       | 22.0                                    | 18.3           |
| Follow-up duration (days) | 13 (4–49)*                              | 19 (4–123)                 | 29 (5–273)              | 23 (5–434)                 | 9 (3–93)*                               | 19 (4–193)    |

Comparisons were evaluated using the chi-squared test for categorical variables, the ANOVA test for normally distributed continuous variables (post hoc analysis of LSD between two groups), and the Kruskal-Wallis test for non-normally distributed continuous variables (Mann-Whitney U test between two groups). The normonatremia group served as a reference for comparison between two groups.

* P < 0.05; † P < 0.01; ‡ P < 0.001; § proportion among dysnatremia group

MV mechanical ventilation, APACHE acute physiology and chronic health evaluation
The AKI causes differed among sodium groups. Hypo-
натremia groups had higher scores for the Charlson 
Comorbidity Index than the normonatremia group. The 
moderate to severe hypernatremia group had higher 
APACHE II scores than the normonatremia group. The 
serum creatinine and albumin levels were similar among 
the sodium groups, except for a higher creatinine 
level in the mild hyponatremia group. Treatment with 
hypertonic saline was used in 8 patients, of whom 7 
had moderate to severe hyponatremia and 1 had mild 
hyponatremia. Hypotonic saline was used in 13 patients 
with mild hypernatremia and 16 patients with moderate 
to severe hypernatremia.

**Risk of mortality according to sodium level**

A total of 57.5% of the subjects died within 30 days 
after starting CRRT. Figure 1 shows the relationship be-
tween baseline sodium level and the predicted probabil-
ity of mortality. The relationship between these variables 
appeared to be U-shaped. Based on this observation, we 
divided the patients into 5 groups, from hyponatremia 
to hypernatremia, and we used the normonatremia group 
as the reference for all of the analyses. The crude 30-day 
mortality rate was as follows: 50.2% of those with normo-
натremia, 62.5% with mild hyponatremia, 65.8% with 
moderate to severe hyponatremia, 51.0% with mild hyper-
натremia, and 70.0% with moderate to severe hypernatre-
mia. Kaplan-Meier survival curves (Fig. 2) show that the 
survival rates were significantly different ($P = 0.016$ among 
the 5 groups, $P = 0.024$ among the Fig. 1a groups, 
and $P = 0.051$ among the Fig. 1b groups). The risks 
of 30-day mortality according to sodium group are 
shown in Table 2. In univariate analysis, both hypo- 
and hypernatremia groups, with the exception of the mild 
hypernatremia group, had greater ORs for mortality than 
the normonatremia group. This trend remained significant 
irrespective of covariates’ effects. Similar to these results, 
the correlation between sodium levels and ORs of mortal-
ity after adjustment for all of the covariates was U-shaped 
(Fig. 3). After initiating CRRT, 542 and 457 patients 
survived at 24 and 72 h, respectively, and their sodium 
levels were included in the subsequent analyses. However, 
sodium levels at 24 and 72 h were not associated with 
mortality risk (Table 3). Additionally, when adjusted for 
the sodium level at baseline, the latter sodium levels did 
not show a significant correlation with mortality (all 
$Ps > 0.05$).

**Sodium correction and mortality**

We further analyzed the risk of mortality according 
to the change in sodium over 24 or 72 h. The num-
ber of 30-day death cases for each group is shown in 
Additional file 2. First, the non-linear relationships 
between adjusted ORs for mortality and changes in 
sodium levels were explored (Fig. 4). In the groups 
with baseline normonatremia or hyponatremia, the 
change in sodium over 24 or 72 h did not show an 
association with the risk of mortality (Fig. 4a to d). In 
the group with baseline hypernatremia (Fig. 4e and f), a 
greater decrease in sodium seemed to incur a reduced risk 
of mortality. However, this trend was shown only in 
the change over 24 h and not over 72 h. In particular, 
comparison of mortality rates within three sodium groups, 
i.e., normonatremia to normonatremia, hyponatremia
to hyponatremia, and hypernatremia to hypernatremia, showed no significant difference (Additional file 3). Moreover, when adjusted for the sodium level at baseline, the change in sodium levels did not have any significance with mortality (all $P$s > 0.05). These results indicated that sodium change and correction of dysnatremia did not change the mortality risk.

**Discussion**

The present study enrolled patients with specific characteristics (extremely severe AKI and high mortality and morbidity risks); thus, CRRT was the preferred method for correction of imbalances in biochemical parameters, including dysnatremia. The results report for the first time a correlation between baseline sodium level and mortality risk in a group undergoing CRRT. However, the change in sodium, as a marker of sodium correction, was not associated with mortality risk. These analyses were helpful in determining whether the correction of dysnatremia independently reduces mortality in the presence of several comorbidities.

Dysnatremia is associated with various negative consequences, such as decreased brain function [3], compromised cardiac contractility [4], increased insulin resistance [14], abnormalities in neuromuscular function [15], creation of an inflammatory milieu [16], and aggravation of interstitial edema [17]. Based on these pathologic conditions, it is plausible that dysnatremia contributes to mortality risk. The present study demonstrated that dysnatremia predicted mortality in a CRRT cohort. For patients undergoing CRRT, any of the negative conditions driven by dysnatremia could have contributed to the high mortality.

Similar to the present results with CRRT, dysnatremia has been associated with high mortality in other several clinical settings, even with normal kidney function [18]. Most studies adjusted for various comorbidities in their analyses, thus suggesting an independent association between sodium and mortality. However, this methodological approach is not sufficient to draw a final conclusion. Other important data are needed, including whether each death is directly related to dysnatremia, and whether the reduction or treatment of dysnatremia itself reduces mortality. A previous analysis of cases with severe hyponatremia indicated that deaths were primarily caused by underlying illness and not by hyponatremia itself [6]. Furthermore, two thirds of those patients died, although their sodium levels returned to normal or near normal ranges. No studies have investigated

**Table 2** Odds ratios for 30-day mortality according to the concentration of serum sodium

| Group                      | Univariate OR (95% CI) | $P$  | Multivariate OR (95% CI) | $P$  |
|----------------------------|------------------------|------|--------------------------|------|
| Moderate to severe hyponatremia | 1.91 (1.197–3.033)     | 0.007| 3.61 (1.438–9.049)       | 0.006|
| Mild hyponatremia          | 1.65 (1.047–2.610)     | 0.031| 2.45 (1.051–5.705)       | 0.038|
| Normonatremia              | 1 (Reference)          |      | 1 (Reference)            |      |
| Mild hypernatremia         | 1.03 (0.560–1.908)     | 0.917| 1.06 (0.461–2.438)       | 0.890|
| Moderate to severe hypernatremia | 2.32 (1.203–4.453)   | 0.012| 2.94 (1.119–7.722)       | 0.029|

*Adjusted for age, sex, enrollment year, weight, cause of acute kidney injury, dialysis dose, need for mechanical ventilation, use of vasoactive drugs, chronic kidney disease, Charlson Comorbidity Index, APACHE II score, creatinine, albumin, urine output, fluid balance, and onset of dysnatremia*
the effects of sodium correction on mortality by using randomization of participants and controlling for confounders.

In addition to the correlation issue between dysnatremia and mortality, it remains unresolved whether the correction of sodium could reduce mortality, particularly in the presence of several comorbidities. A study of this issue is difficult to conduct. Thus, the present study might be helpful, despite its observational design, in understanding the correlation. In contrast to the baseline level, subsequent sodium levels did not predict mortality irrespective of timeframe (24 and 72 h), possibly because of case-mix results, such as the group with baseline dysnatremia later having normonatremia. Furthermore, the change in sodium level, including the appropriate correction of dysnatremia, was not correlated with mortality. These results suggested that sodium level itself might accurately predict mortality in association with comorbidities or other related factors; however, the correction of sodium alone did not contribute to a survival benefit, particularly under the strong influence of comorbidities.

The association with mortality may differ for hyponatremia and hypernatremia. In the present cohort, mild hypernatremia was not associated with mortality in contrast to the results of mild hyponatremia. The discrepancy between the effects of hypo- and hypernatremia has been reported in other observational studies [19–21]. Each association with mortality could be sensitive to the disease state of study. However, although the baseline characteristics differ across studies, hyponatremia and hypernatremia should be considered separately in research, as well as in clinical practice.

Although the present results are informative, this study has some limitations. First, the observational study design limits the drawing of conclusions, because of causality. However, randomized trials of dysnatremia treatment to determine survival benefit are not feasible,

Table 3 Adjusted odds ratios for 30-day mortality according to sodium level after 24 and 72 h

| Group                        | 24-h sodium OR (95 % CI) | P     | 72-h sodium OR (95 % CI) | P     |
|------------------------------|--------------------------|-------|--------------------------|-------|
| Moderate to severe hyponatremia | 0.81 (0.458–1.418)       | 0.454 | 0.89 (0.524–1.528)       | 0.683 |
| Mild hyponatremia             | 1.08 (0.629–1.868)       | 0.771 | 1.08 (0.637–1.825)       | 0.780 |
| Normonatremia                 | 1 (Reference)            |       | 1 (Reference)            |       |
| Mild hypernatremia            | 0.90 (0.270–3.027)       | 0.869 | 4.69 (0.835–26.302)      | 0.079 |
| Moderate to severe hypernatremia | 6.33 (0.794–50.382)     | 0.081 | 3.13 (0.606–16.156)      | 0.173 |

*Adjusted for age, sex, enrollment year, weight, cause of acute kidney injury, dialysis dose, need for mechanical ventilation, use of vasoactive drugs, chronic kidney disease, Charlson Comorbidity Index, APACHE II score, creatinine, albumin, urine output, fluid balance, and onset of dysnatremia

OR odds ratio, CI confidence interval
particularly in the presence of comorbidities; thus, the present results might be helpful in raising awareness of the correlation between sodium correction and outcomes. Second, the present cohort of patients who underwent CRRT is a particular subgroup, thus hindering the applicability of the conclusions to other populations. Furthermore, a single therapeutic intervention (i.e., sodium correction) might not show a survival benefit under conditions of high comorbidity rates of CRRT patients [22]. Third, sodium levels corrected for

**Fig. 4** Non-linear relationships between the adjusted odds ratio of 30-day mortality and changes in sodium in the normonatremia (a, b), hyponatremia (c, d), and hypernatremia (e, f) groups. Figures (a), (c), and (e) show the relationships with changes over 24 h. Figures (b), (d), and (f) show the relationships with changes over 72 h.
glucose may not be accurate, because the correction factor may be altered by patient characteristics or high glucose states [23, 24]. Lastly, we did not retrieve important variables (e.g., correction rate of dysnatremia and neurologic outcomes), which could affect the overall outcome.

Conclusions
Sodium level at the start of CRRT was a strong predictor of mortality, as previously observed in other clinical settings. However, the impact of sodium correction on mortality was not significant, and would have been weaker in the presence of multiple comorbidities or severe disease, both of which have been correlated with dysnatremia. Randomized controlled studies are needed to draw a firm conclusion, but the present study may be helpful in understanding the meaning of sodium levels and applying it in clinical practice.

Additional files

Additional file 1: CONSORT flow diagram. (PDF 171 kb)
Additional file 2: Subject number according to the change of serum sodium during 24 or 72 hours. (DOCX 38 kb)
Additional file 3: Adjusted odd ratios of mortality among the sodium groups such as normonatremia-to-normonatremia, hyponatremia-to-hyponatremia, and hypernatremia-to-hyponatremia. (DOCX 28 kb)

Abbreviations
AKI: acute kidney injury; APACHE: acute physiology and chronic health evaluation; CI: confidence interval; CRRT: continuous renal replacement therapy; OR: odds ratio.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
SSH designed the study, collected the data, analyzed and interpreted the results, and drafted the manuscript. EB collected the data. DKK and YSK designed the study, collected the data, analyzed and interpreted the results, and reviewed the manuscript. All of the authors read and approved the final manuscript.

Acknowledgements
None.

Received: 3 March 2015 Accepted: 22 December 2015
Published online: 05 January 2016

References
1. Hoorn EJ, Zietse R. Hyponatremia and mortality: moving beyond associations. Am J Kidney Dis. 2013;62(1):139–49.
2. Lindner G, Funk GC, Schwarzwald M, Kneidinger N, Kaider A, Schneeveis B, et al. Hyponatremia in critically ill is an independent risk factor for mortality. Am J Kidney Dis. 2007;50(6):373–83.
3. Aranyi Z, Kovacs T, Szirmai I, Vastagh I. Reversible nerve conduction slowing in hyponatremia. J Neurol. 2004;251(12):1532–7.
4. Kovacs CP, Noll DJ, Burrell DH, Callaway CW, Gurney JG, Hoylake PJ, et al. In vivo effects of acute changes in osmolality and sodium concentration on myocardial contractility. Am Heart J. 1985;109(2):290–6.
5. Mohammed AA, van Kimmenade RR, Richards M, Bayes-Genis A, Pinto Y, Moore SA, et al. Hyponatremia, natriuretic peptides, and outcomes in acutely decompensated heart failure: results from the International Collaborative of NT-proBNP Study. Circ Heart Fail. 2010;3(3):354–61.
6. Chawla A, Sterns RH, Nigwekar SU, Cappuccio JD. Mortality and serum sodium: do patients die from or with hyponatremia? Clin J Am Soc Nephrol. 2011;6(5):960–5.
7. Dixon MB, Lien YH. Tolvaptan and its potential in the treatment of hyponatremia. Ther Clin Risk Manag. 2008;4(6):149–55.
8. Hoste EA, Schurgers M. Epidemiology of acute kidney injury: how big is the problem? Crit Care Med. 2008;36(4 Suppl):S146–51.
9. Charlton ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.
10. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–29.
11. Katz MA. Hyperglycemia-induced hyponatremia—calculation of expected serum sodium depression. N Engl J Med. 1973;289(16):843–4.
12. Yesilyurt L, Yee J, Frink S, Szamosfalvi A. Treatment of severe hyponatremia in patients with kidney failure: role of continuous venovenous hemofiltration with low-sodium replacement fluid. Am J Kidney Dis. 2014;64(2):305–10.
13. Huang C, Zhang P, Du R, Li Y, Yu Y, Zhou M, et al. Treatment of acute hyponatremia in severely burned patients using continuous veno-venous hemofiltration with gradient sodium replacement fluid: a report of nine cases. Intensive Care Med. 2013;39(8):1495–6.
14. Bratusch-Marrain PR, DeFronzo RA. Impairment of insulin-mediated glucose metabolism by hyperosmolality in man. Diabetes. 1983;32(11):1028–34.
15. Knochel JP. Neuromuscular manifestations of electrolyte disorders. Am J Med. 1982;72(3):521–35.
16. Jensen AG, Wachmann CH, Poulsen KB, Espersen F, Scheibl J, Skinhøj P, et al. Risk factors for hospital-acquired Staphylococcus aureus bacteremia. Arch Intern Med. 1999;159(13):1437–44.
17. Thijsen S, Raimann JG, Usvyat LA, Levin NW, Kotanko P. The evils of intradialytic sodium loading. Contrib Nephrol. 2011;171:84–91.
18. Kovesdy CP. Significance of hypo- and hyponatremia in chronic kidney disease. Nephrol Dial Transplant. 2012;27(3):891–8.
19. Stewart IJ, Morrow BD, Tilley MA, Snow BD, Gisler C, Kramer KW, et al. Dysnatremias and survival in adult burn patients: a retrospective analysis. Am J Nephrol. 2013;37(1):59–64.
20. Kovesdy CP, Lott EH, Lu J, Malakauskas SM, Ma JZ, Molnar MZ, et al. Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure. Circulation. 2012;125(5):677–84.
21. Funk GC, Lindner G, Druml W, Metnitz B, Schwarz C, Bauer P, et al. Incidence and prognosis of dysnatremias present on ICU admission. Intensive Care Med. 2010;36(2):304–11.
22. Greenberg A, Verbalis JG, Amin AN, Burst VR, Chiodo 3rd JA, Chiong JR, et al. Current treatment practice and outcomes. Report of the hyponatremia registry. Kidney Int. 2015;88(1):1167–77.
23. Penne EL, Thijsen S, Raimann JG, Levin NW, Kotanko P. Correction of serum sodium for glucose concentration in hemodialysis patients with poor glucose control. Diabetes Care. 2010;33(7):e91.
24. Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction for hyperglycemia. Am J Med. 1999;106(4):399–403.